New Pharmacological Treatment for Obstructive Sleep Apnea
Phase 1
Completed
- Conditions
- Obstructive Sleep Apnea
- Registration Number
- NCT00108498
- Lead Sponsor
- US Department of Veterans Affairs
- Brief Summary
This study will determine if mirtazapine, a unique antidepressant that does not disturb sleep, will improve obstructive sleep apnea (OSA). The design is randomized, crossover, double blind, and placebo controlled. On two consecutive nights of one week, the patients receive either 30 mg mirtazapine or placebo at bedtime. The following week, the alternative medication is administered. The patients have known mild to moderate sleep apnea. The endpoints of the study are the apnea + hypopnea index (AHI), sleep quality, and the degree of arterial oxygen desaturation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Known OSA mild to moderate
Exclusion Criteria
- On antidepressant or antipsychotic medications
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method The apnea + hypopnea index (AHI) Sleep quality The degree of arterial oxygen desaturation
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Malcom Randall VAMC
🇺🇸Gainesville, Florida, United States